ATX-559

Accent Therapeutics has dosed the first patient in a Phase I/II trial of ATX-295, an oral KIF18A inhibitor targeting solid tumors, including high-grade serious ovarian cancer.

Accent Therapeutics will present preclinical data on ATX-559, a first-in-class DHX9 inhibitor targeting cancers with genomic instability, currently in Phase 1/2 trials for BRCA-deficient breast cancer and MSI-H/dMMR solid tumors.

Accent Therapeutics initiated a Phase 1/2 clinical trial for ATX-559, a first-in-class DHX9 inhibitor, focusing on BRCA1/2-deficient breast cancer and MSI-H/dMMR solid tumors.

Accent Therapeutics received FDA clearance for its IND application for ATX-559, a first-in-class DHX9 inhibitor, marking a significant step toward clinical trials.